BioInformant

Your Global Leader in Stem Cell Market Research

American Journal of Sports Medicine to publish results of an FDA-approved clinical trial for treating knee pain

By 1 Comment

Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees

GID BioLouisville, Colo. and Chicago, Ill. – January 30, 2020 – GID BIO announced the acceptance by the American Journal of Sports Medicine to publish results next month of an FDA-approved multi-site, randomized, placebo-controlled Phase IIb clinical trial measuring the safety and efficacy of its SVF-2 device and point-of-care (POC) therapy intended to treat pain and function associated with knee osteoarthritis. [Read more…]

TreeFrog Therapeutics brings in senior profiles to drive the advent of high-quality & affordable allogenic cell therapies

By Leave a Comment

Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-StemTM technology for cell therapy mass-production.

Bordeaux, France, February 5, 2020 – TreeFrog Therapeutics, a pure player in iPSC-derived cell therapies, today announces the appointment of 2 senior executives and 2 independent board members. Pascale Berthet, formerly Business Development Manager at FUJIFILM Cellular Dynamics was appointed Chief Business Development Officer, and Michaël Lanero Fidalgo, former Head of EMEA Biodevelopment Center at Merck KGaA, was recruited as Chief Operating Officer. In addition, 2 independent board members joined TreeFrog Therapeutics’ corporate governance: Julia Berretta, formerly VP of Business Development at Cellectis, and Frederic Desdouits, former Bionest Partner and Pierre Fabre North America director. [Read more…]

How Anemocyte is Changing History as a Biotech Manufacturing Organization (BMO)

By Leave a Comment

AnemocyteHeadquartered in Milano, Italy, Anemocyte is the world’s first company to identify as a Biotech Manufacturing Organization (BMO). The company’s Cell Therapy Platform supports the manufacturing of autologous and allogeneic products, its DNA Platform produces plasmid DNA for viral vector production, and its Gene Therapy Platform supports process development and implementation for non-viral gene modified cells.

[Read more…]

Professional Short Course on “Preservation of Cellular Therapies” by University of MN

By Leave a Comment

Minneapolis, MN (University of MN)
May 18-19, 2020     

Preservation of Cellular Therapies is a professional short course founded in 2003 to provide practical training for those individuals involved in the preservation of cellular therapies. The course is associated with the Biopreservation Core Resource at the University of Minnesota. The short course will be held again in Minneapolis, MN, from May 18-19, 2020.

[Read more…]

Stem Cells in Drug Discovery: A Changing Paradigm

By Leave a Comment

Drug discovery involves high cost and uncertain outcomes.  Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerging during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing.

Now, some new medicines are being tested for safety on specialized cells developed from human pluripotent cell lines. Cells types which are frequently being using within drug discovery applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur. [Read more…]

BioInformant's World-Class Clients